Clinical Report: Prior Authorization Strategies to Prevent Surgical Payment Delays

Overview

The expansion of prior authorization (PA) requirements for ophthalmic surgeries in ambulatory surgery centers (ASCs) is significantly impacting scheduling, documentation, and revenue cycles. Understanding these requirements is crucial for ASCs to minimize reimbursement disruptions and ensure compliance with Medicare policies.

Background

Prior authorization has become a standard procedure in surgical reimbursement, particularly in ophthalmology, due to recent CMS policy changes and the growth of Medicare Advantage plans. These changes necessitate that ASCs adapt their workflows to accommodate new authorization requirements, which can affect patient care and operational efficiency. As the number of surgical cases requiring PA increases, it is essential for healthcare providers to understand the implications of these policies.

Data Highlights

No numerical data provided in the article.

Key Findings

• CMS is expanding PA requirements for certain procedures in ASCs starting in 2026.
• Nearly 53 million prior authorization determinations were processed by Medicare Advantage insurers in 2024.
• Documentation supporting medical necessity is critical for PA approval, particularly for eyelid surgeries and botulinum toxin procedures.
• Clear communication between physician offices and ASCs is essential to prevent missed authorizations.
• Authorization requests must include CPT codes and supporting diagnosis codes to demonstrate medical necessity.

Clinical Implications

Healthcare providers must ensure that prior authorization requests are submitted timely and that documentation accurately reflects medical necessity to avoid reimbursement delays. Training staff on coding and documentation practices can enhance compliance with PA requirements.

Conclusion

As prior authorization requirements continue to evolve, understanding and adapting to these changes will be vital for ASCs to maintain operational efficiency and ensure patient access to necessary surgical procedures.

References

1. Ophthalmology Management, 2025 -- CMS Delays ASC Prior Authorization Program to 2026
2. The ASCO Post, 2025 -- Prior Authorization Is Burdensome for Patients and Results in Treatment Delays, Financial Strain, and Stress
3. Ophthalmic Professional, 2025 -- Insights on Prior Authorization
4. CMS -- Biden-Harris Administration Finalizes Rule Expanding Access to Care and Increasing Protections for People with Medicare Advantage and Medicare Part D
5. CMS -- CMS Interoperability and Prior Authorization Final Rule CMS-0057-F
6. Ophthalmology Management — ASC Reimbursement Strategies in Ophthalmology in 2026
7. Biden-Harris Administration Finalizes Rule Expanding Access to Care and Increasing Protections for People with Medicare Advantage and Medicare Part D | CMS
8. CMS Interoperability and Prior Authorization Final Rule CMS-0057-F | CMS
9. Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices | Clinical Pharmacy and Pharmacology | JAMA Ophthalmology | JAMA Network